文献速递中枢神经肿瘤放疗消化道肿瘤放疗姑息放疗与转移瘤

同期放射外科与靶向肿瘤治疗改善胃肠道癌脑转移患者的预后

Concomitant radiosurgical and targeted oncological treatment improves the outcome of patients with brain metastases from gastrointestinal cancer.
PubMed 文献 · Radiat Oncol · 2023-12-09

本研究评估接受伽玛刀放射外科(GKRS)并同期免疫治疗(IT)或靶向治疗(TT)的胃肠道癌脑转移患者。多变量Cox回归显示,首次GKRS时或之后接受IT或TT是总生存的唯一显著预测因素,且不增加不良放射效应发生率,局部脑转移进展无显著差异。

要点

  • 首次GKRS时或之后接受IT或TT是总生存的唯一显著预测因素
  • 同期IT或TT未增加不良放射效应发生率
  • 接受与未接受IT或TT患者间局部脑转移进展无显著差异

核心结论

  • GKRS对胃肠道癌脑转移患者具有良好的局部肿瘤控制率和低副作用发生率,表明其安全有效。
  • 同期放射外科与靶向肿瘤治疗显著改善GKRS后生存,且不增加不良放射效应发生率。
  • 为提供局部肿瘤控制,放射外科在现代胃肠道癌脑转移管理中仍至关重要。

研究设计与样本

  • 比较GKRS后生存与一般及特异性分级预后评估(GPA)和放射外科评分指数(SIR)。
  • 分析年龄、性别、卡氏功能状态评分(KPS)、脑转移诊断时颅外转移(ECM)状态、脑转移数目、递归 partitioning 分析(RPA)分级、GKRS1治疗模式及同期IT或TT对GKRS后生存的影响。
  • 报告同期GKRS与主要为TT治疗的并发症发生率。

主要发现

  • 多变量Cox回归分析显示,首次伽玛刀放射外科(GKRS1)治疗时或之后接受IT或TT是GKRS1后总生存的唯一显著预测因素,即使在调整性别、KPS分组、年龄分组、GKRS1时脑转移数目、RPA分级、脑转移诊断时ECM状态和GKRS治疗模式后仍显著。
  • 同期IT或TT治疗未增加不良放射效应发生率。
  • 接受IT或TT与未接受IT或TT的患者之间,GKRS后局部脑转移进展无显著差异。

临床怎么用

  • 作者结论认为,同期放射外科与靶向肿瘤治疗显著改善GKRS后生存且不增加不良放射效应发生率。
  • 作者结论认为,为提供局部肿瘤控制,放射外科在现代胃肠道癌脑转移管理中仍至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: So far, only limited studies exist that evaluate patients with brain metastases (BM) from GI cancer and associated primary cancers who were treated by Gamma Knife Radiosurgery (GKRS) and concomitant immunotherapy (IT) or targeted therapy (TT). METHODS: Survival after GKRS was compared to the general and specific Graded Prognostic Assessment (GPA) and Score Index for Radiosurgery (SIR). Further, the influence of age, sex, Karnofsky Performance Status Scale (KPS), extracranial metastases (ECM) status at BM diagnosis, number of BM, the Recursive Partitioning Analysis (RPA) classes, GKRS1 treatment mode and concomitant treatment with IT or TT on the survival after GKRS was analyzed. Moreover, complication rates after concomitant GKRS and mainly TT treatment are reported. RESULTS: Multivariate Cox regression analysis revealed IT or TT at or after the first Gamma Knife Radiosurgery (GKRS1) treatment as the only significant predictor for overall survival after GKRS1, even after adjusting for sex, KPS group, age group, number of BM at GKRS1, RPA class, ECM status at BM diagnosis and GKRS treatment mode. Concomitant treatment with IT or TT did not increase the rate of adverse radiation effects. There was no significant difference in local BM progression after GKRS between patients who received IT or TT and patients without IT or TT. CONCLUSION: Good local tumor control rates and low rates of side effects demonstrate the safety and efficacy of GKRS in patients with BM from GI cancers. The concomitant radiosurgical and targeted oncological treatment significantly improves the survival after GKRS without increasing the rate of adverse radiation effects. To provide local tumor control, radiosurgery remains of utmost importance in modern GI BM management.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Khalaveh F, Cho A, Shaltout A, et al. Concomitant radiosurgical and targeted oncological treatment improves the outcome of patients with brain metastases from gastrointestinal cancer. Radiat Oncol. 2023. PMID: 38071299. doi:10.1186/s13014-023-02383-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。